CoChat

Scientific rationale for combination immunotherapy of hepatocellular carcinoma with anti–PD-1/PD-L1 and anti–CTLA-4 antibodies

Open access
Kudo, Masatoshi · 2019 · Liver Cancer

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Abstract

The outcomes of immune checkpoint inhibitor therapies against advanced cancer have greatly exceeded initial expectations since the early clinical studies reported in 2010 [1] and 2012 [2]. It is now evident that immune checkpoint inhibitors are highly effective against multiple solid tumors in addition to malignant melanoma, which was the first malignancy to be studied. Although researchers were initially skeptical about the practical use of conventional cancer immunotherapies that solely enhance immune responses, scientists in both industry and academia are vigorously pursuing the development of anticancer immunotherapies using immune checkpoint inhibitors. In fact, the journal Science designated cancer immunotherapy as the “Breakthrough of the Year” in 2013, and the journal Nature named immune checkpoint blockade in cancer a paradigm shift in cancer treatment. Since then, various industry-academia collaborations have been initiated, and the remarkable strides in this field have been hailed as “the dawn of the new cancer therapy era” [3] and the “renaissance of cancer immunotherapy” [4]. The first immune checkpoint molecule to be described, programmed cell death protein 1 (PD-1), was identified in 1992 by Dr. Tasuku Honjo and colleagues at Kyoto University [5]. Published online: September 27, 2019

Overview

Integrity signals

Registry

Crossref · 10.1159/000503254

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 54 references

Cited by

See all 71

Metadata

Authors
Kudo, M.
Affiliations
Kindai University Hospital (JP)
Corresponding author
Kudo, Masatoshi
Venue
Liver Cancer
Publisher
S. Karger AG
Published
2019
Volume
8
Issue
6
Pages
413-426
ISSN
  • 1664-5553 (ISSN-L)
  • 2235-1795
OpenAlex
W2976901627
Cited by
70
References
54
Citations by year
2026: 3 · 2025: 13 · 2024: 9 · 2023: 18 · 2022: 11 · 2021: 10 · 2020: 5
FWCI
2.82
Type
journal article
Language
en
Open access
Licence
Locations
  • Liver Cancer (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
Keywords
hepatocellular carcinoma, combination immunotherapy, anti-PD-1, PD-L1 inhibitors, anti-CTLA-4 antibody, immune checkpoint inhibitors, tumor immunology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.